Nanjing KeyGen Biotech. Co. Ltd., founded in Nov. 2000, is a high-tech company, which focuses on R&D on innovative medicines and approaches to treating cancer. The main shareholder of KeyGen is Nanjing Medical Group Co., Ltd (NMG), one of top ten strongest Chinese pharmaceutical enterprises and one of the five largest Groups in Nanjing. We have set up a drug discovery platform with self-regulated intellectual property KeyGen Human Genomic Regulatory Database (HGRD) that is based on the cutting-edge genomic research and bioinformatics. The innovative anti-cancer decoy oligonucleotide drug KGCGS102 have got 4 Chinese patents, 3 international patents are in application process. Based on the core-technology of KeyGen during the anti-cancer new drug development, KeyGen has developed and marketed over 1400 reagents for life science research in the fields of cell biology, molecular biology, protein research.